Merck acquires Terns Pharmaceuticals

Merck has finalized its acquisition of Terns Pharmaceuticals, Inc., a move aimed at bolstering its oncology portfolio, particularly in the area of chronic myeloid leukemia (CML). The transaction, valued at approximately $6.7 billion, underscores Merck's strategy to enhance its pipeline with innovative therapeutic options. This acquisition brings TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, into Merck's fold. TERN-701 holds promise for treating certain CML patients, especially those who have previously been treated with multiple TKIs.

The acquisition process was executed through a cash tender offer by Merck, offering $53.00 per share for all outstanding common stock of Terns, resulting in the acquisition of approximately 86.36% of shares by the offer's expiry in May 2026. Following the tender offer, Merck accomplished the acquisition through a merger, converting remaining shares into cash at the same offer price. This merger results in Terns becoming a wholly-owned subsidiary of Merck, with its shares delisted from the Nasdaq.

Merck's Chief Executive, Robert M. Davis, described the acquisition as a continuation of the company's commitment to scientific innovation in developing meaningful treatments. The strategic acquisition of TERN-701 is viewed as potentially differentiating in the CML treatment landscape, poised to elevate the standard of care for specific patient populations. TERN-701 has already garnered attention after receiving Breakthrough Therapy Designation from the FDA for adults with Philadelphia chromosome-positive CML in chronic phase lacking the T315I mutation.

This acquisition reflects broader trends in the pharmaceutical sector where large firms like Merck actively acquire companies to expand pipelines and leverage breakthrough innovations in specialized areas such as oncology. For Merck, TERN-701's integration promises not only to diversify but potentially enhance its competitive positioning in the lucrative hematology market, a key growth area given the increasing incidence of leukemia. Competitors in the oncology sector may feel the competitive heat as Merck accelerates clinical development and commercialization of this candidate.

Looking ahead, the acquisition is slated to be recorded as an asset acquisition, impacting Merck's financials with an expected R&D expense charge of approximately $5.8 billion for the year 2026. Earnings per share are anticipated to decline by about $0.12 per share due to related expenses. The successful development and commercialization of TERN-701 will be critical for mitigating these financial impacts, with Merck focused on advancing clinical trials and potential regulatory approvals in the near future.